TransMedics Group, Inc. (NASDAQ:TMDX) Insider Tamer I. Khayal Sells 2,958 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total value of $438,493.92. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $3,089,766.32. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $138.97 on Friday. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The company has a market cap of $4.64 billion, a P/E ratio of -408.74 and a beta of 1.99. TransMedics Group, Inc. has a 52 week low of $36.42 and a 52 week high of $177.37. The company has a 50-day moving average price of $156.02 and a 200 day moving average price of $134.13.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. The firm had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The firm’s revenue was up 117.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.03) earnings per share. Research analysts predict that TransMedics Group, Inc. will post 1.22 earnings per share for the current year.

Institutional Investors Weigh In On TransMedics Group

A number of hedge funds have recently added to or reduced their stakes in TMDX. Wasatch Advisors LP acquired a new stake in TransMedics Group in the first quarter valued at about $32,162,000. Vaughan Nelson Investment Management L.P. acquired a new stake in shares of TransMedics Group during the 2nd quarter valued at approximately $39,862,000. Driehaus Capital Management LLC lifted its position in shares of TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after acquiring an additional 202,867 shares during the period. First Light Asset Management LLC lifted its position in shares of TransMedics Group by 22.0% during the 4th quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock valued at $59,538,000 after acquiring an additional 136,217 shares during the period. Finally, Hood River Capital Management LLC acquired a new stake in shares of TransMedics Group during the 2nd quarter valued at approximately $18,854,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TMDX. Morgan Stanley raised their price objective on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Piper Sandler raised their price objective on TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Stephens raised their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Robert W. Baird assumed coverage on TransMedics Group in a report on Tuesday, September 24th. They set an “outperform” rating and a $200.00 price target on the stock. Finally, Baird R W raised TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, TransMedics Group currently has an average rating of “Buy” and an average price target of $174.30.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.